Nutrition in acute and chronic diseases

Vitamin C and folate status in hereditary fructose intolerance

Ainara Cano1,2, Carlos Alcalde3, Amaya Belanger-Quintana4, Elvira Cañedo-Villarroya5, Leticia Ceberio1,6, Silvia Chumillas-Calzada7, Patricia Correcher8, María Luz Couce9, Dolores García-Arenas10, Igor Gómez11, Tomás Hernández12, Elsa Izquierdo-García13, Dámaris Martínez Chicano10, Montserrat Morales7, Consuelo Pedrón-Giner5, Estrella Petrina Jáuregui14, Luis Peña-Quintana15, Paula Sánchez-Pintos9, Juliana Serrano-Nieto16, María Unceta Suarez17, Isidro Vitoria Miñana8 and Javier de las Heras8,18,19

© The Author(s) 2022, corrected publication 2023

BACKGROUND: Hereditary fructose intolerance (HFI) is a rare inborn error of fructose metabolism caused by the deficiency of aldolase B. Since treatment consists of a fructose-, sucrose- and sorbitol-restrictive diet for life, patients are at risk of presenting vitamin deficiencies. Although there is no published data on the status of these vitamins in HFI patients, supplementation with vitamin C and folic acid is common. Therefore, the aim of this study was to assess vitamin C and folate status and supplementation practices in a nationwide cohort of HFI patients.

METHODS: Vitamin C and folic acid dietary intake, supplementation and circulating levels were assessed in 32 HFI patients and 32 age- and sex-matched healthy controls.

RESULTS: Most of the HFI participants presented vitamin C (96.7%) and folate (90%) dietary intake below the recommended population reference intake. Up to 69% received vitamin C and 50% folic acid supplementation. Among HFI patients, 15.6% presented vitamin C and 3.1% folate deficiency. The amount of vitamin C supplementation and plasma levels correlated positively ($R = 0.443$; $p = 0.011$). Interestingly, a higher percentage of non-supplemented HFI patients were vitamin C deficient when compared to healthy controls (30% vs. 3.1%; $p = 0.036$).

CONCLUSIONS: Our results provide evidence for the first time supporting vitamin C supplementation in HFI. There is great heterogeneity in vitamin supplementation practices and, despite follow-up at specialised centres, vitamin C deficiency is common. Further research is warranted to establish optimal doses of vitamin C and the need for folic acid supplementation in HFI.

European Journal of Clinical Nutrition (2022) 76:1733–1739; https://doi.org/10.1038/s41430-022-01178-3

INTRODUCTION

Hereditary fructose intolerance (HFI; OMIM 229600) is a rare, autosomal-recessive inborn error of metabolism caused by deficiency of the enzyme fructose-1,6-bisphosphate aldolase (aldolase B; E.C. 4.1.2.13) [1]. Aldolase B regulates both glycolysis and gluconeogenesis, catalysing various reactions such as cleavage of fructose-1-phosphate and reversible cleavage of fructose-1,6-bisphosphate. It is expressed in the cytoplasm of hepatocytes, renal tubules, and in the small intestine [2]. Although the prevalence of HFI is estimated to be between 1:20,000 and 1:31,000 in certain European populations, recent data shows that HFI may have a wider distribution and higher prevalence than expected (circa 1:10,000) [3].

Symptoms in HFI patients usually initiate 5 or 6 months after birth due to the introduction of complementary feeding in the infant. After fructose ingestion, children usually present failure to thrive, accompanied by nausea, vomiting, and abdominal pain. Persistent intake of fructose may lead to hypoglycaemia, jaundice, metabolic acidosis, seizures, coma, liver cirrhosis, and eventual death [4–6]. Despite HFI treatment, which consists of a fructose-, sucrose- and sorbitol (FSS)-restricted diet for life [7], some HFI patients present long-term complications, such as hepatic steatosis [8].

Received: 9 March 2022 Revised: 17 June 2022 Accepted: 23 June 2022
Published online: 19 July 2022
Vitamin C, also known as L-ascorbic acid, is a water-soluble essential micronutrient naturally found in fresh fruit and vegetables, e.g. oranges, lemons, limes, potatoes, grapefruit, broccoli, red peppers, spinach and tomatoes [9]. This vitamin is involved in various enzyme reactions, such as redox balance maintenance and iron absorption [10]. It has been reported that vitamin C reduces systemic inflammation, helps correct sepsis-induced coagulopathy and prevents vascular injury, and its circulating levels are also inversely associated with metabolic syndrome [11, 12].

Folate is a generic term that typically refers to a group of compounds that belong to the family of B-vitamins. Also known as vitamin B9, folic acid is the synthetic form of folate. This vitamin can be found in legumes, meat, milk, eggs and vegetables like spinach, broccoli, and lettuce [9]. Folate participates in tissue growth, helps in the production of DNA and RNA, contributes to the maturation of erythrocytes and, together with vitamin C, participates in protein metabolism [13]. A deficiency of folate usually results from chronic alcoholism, malabsorption disorders, haemolytic anaemia, increased requirements during pregnancy, or a diet poor in this compound [9].

Since HFI treatment consists of a FSS-restrictive diet for life, HFI patients are at risk of presenting vitamin deficiencies. Although there are no clinical guidelines for this rare disease, supplementation with vitamin C and/or folic acid is common. To the best of our knowledge, there is no published data on vitamin status in HFI patients. Therefore, the aim of this study was to assess vitamin C and folate status and supplementation practices in a nationwide cohort of HFI patients.

PATIENTS AND METHODS

Study design and participants

Recruitment for this cross-sectional study was conducted from October 2019 to November 2020. Study visits were carried out at Cruces University Hospital, Spain. The study population for this study comprised 32 genetically diagnosed HFI patients and 32 age- and sex-matched healthy controls. No sample size calculation was performed, all available HFI patients with data on vitamin C and folate status were included in the study.

Eleven Spanish hospitals participated in the study: Cruces University Hospital [host] (n = 6), Araba University Hospital (n = 2), Albacete University Hospital (n = 1), Navarra University Hospital (n = 2), 12 de Octubre University Hospital (n = 4), Niño Jesús University Children’s Hospital (n = 3), Ramón y Cajal University Hospital (n = 5), La Fe University Hospital (n = 2), Málaga Regional University Hospital (n = 1), Rio Hortega University Hospital (n = 2) and Mother and Child Insular University Hospital (n = 4).

All the HFI patients were on a FSS-restricted diet for at least 2 years.

Ethics

The study protocol was carried out according to the ethical guidelines of the revised 1975 Declaration of Helsinki [14] and approved by the Basque Ethics Committee for Research (CEIm-E), ethical approval code: PI20190972. Written informed consents were obtained from parents or legal guardians of children (below 18 years of age) and adult study participants.

Dietary intake

Dietary intake was collected in a self-administered nutritional record of dietary intake on 3 days (two during the week and one at the weekend) in 30 HFI patients and in 28 non-HFI healthy controls. Once completed, vegetable fibre, vitamin C and folate daily intake were calculated using the Nutritional Calculation DIAL programme (Version 3.10.5.0) [15]. In addition, information regarding vitamin C and folic acid supplementation was collected from all the study participants.

Biochemical analyses

Circulating concentrations of ascorbate (vitamin C) and folate were determined in all study subjects by routine clinical techniques. Briefly, vitamin C in plasma was quantified by high performance liquid chromatography with electrochemical detection. Vitamin C levels ≤23 μmol/L were considered to be hypovitaminosis and values ≤11 μmol/L as vitamin C deficiency [16, 17]. The quantitative determination of folate in serum was carried out by the Atellica® IM Folate assay for in vitro diagnostic use. Concentrations under 6.8 nmol/L were considered to be folate deficiency [18].

Statistical analysis

Data are presented as mean ± standard deviation or median and range (minimum-maximum), depending on data distribution. Continuous variables were compared by unpaired Student’s t test or Mann–Whitney U test. Differences in categorical variables were assessed using χ² or Fisher’s exact test. P values were based on two-tailed comparisons and those under 0.05 were considered to indicate a statistically significant difference. In order to assess bivariate relationships between variables, Pearson or Spearman Rank test correlation analyses were used. All the statistical analysis tests were subject to data distribution and were carried out using SPSS software, version 23 for Windows (IBM, Chicago, IL).

RESULTS

Study cohort

The study population comprised 32 genetically diagnosed HFI patients and 32 healthy controls, all of them of Caucasian origin. Clinical characteristics of the study participants are shown in Table 1. There were no significant differences in weight, body mass index (BMI), age, and sex between HFI and control subjects (Table 1).

Dietary intake in HFI patients

Vitamin C dietary intake was markedly lower in HFI patients when compared to their controls (23.8 [6.4–76.1] mg/day vs. 107.0 [42.8–346.6]; p < 0.001) (Table 1). Folate daily dietary intake was also significantly lower in HFI patients than in controls (183.5 [78.6–304.3] μg/day vs. 202.2 [115.8–524.2] μg/day; p = 0.027) (Table 1). Among the HFI participants, 96.7% had a vitamin C dietary intake below the recommended daily vitamin C population reference intake (PRI) and 90% had a folate dietary intake below the recommended PRI (Table 2).

Vitamin C and folic acid supplementation

Table 2 shows vitamin C and folic acid dietary intake, supplementation and circulating levels in HFI patients. Of the 32 HFI patients studied, 22 (69%) received vitamin C and 16 (50%) folic acid supplementation from single and/or multivitamin supplements (Fig. 1). Eleven HFI patients (34%) were prescribed different multivitamin supplements containing, among others, different amounts of vitamin C and folic acid (Table 2). In contrast, no control subject took either vitamin C or folic acid supplements. All the different multivitamin supplements consumed by the study participants and depicted in Table 2 contain both vitamin C and folic acid, except Supradyn® Protovit, which does not contain folic acid.

Vitamin C status

Among the HFI patients, 7 (21.9%) presented vitamin C hypovitaminosis/deficiency, with 5 patients (15.6%) with circulating vitamin C values below 11 μmol/L. Twenty-two out of 32 HFI patients received vitamin C supplementation, and there were no differences in plasma vitamin C levels or the percentage of vitamin C deficiency between HFI patients and healthy controls (Table 1). Taking into account vitamin C supplementation, although there were no significant differences in vitamin C levels between non-supplemented HFI patients and healthy controls (Table 1), there were no significant differences among HFI patients with vitamin C supplementation. Among the HFI patients, 5 patients (15.6%) with circulating vitamin C values below 11 μmol/L; p = 0.154), a higher percentage of non-supplemented HFI patients presented vitamin C deficiency (30% vs. 3.1%; p = 0.036) (Fig. 2).

Within the HFI group, although the patients that were not given vitamin C supplements presented lower circulating levels than
those who were given supplements (32.9 [5.7–76.7] µmol/L vs. 59.1 [6.8–138] µmol/L; \( p = 0.047 \)), there were not statistically significant differences in the percentage of vitamin C deficiency (30% vs. 9.1%; \( p = 0.293 \)). The amount of vitamin C supplementation and plasma levels correlated positively (\( R = 0.443; \ p = 0.011 \)) (Fig. 3).

**DISCUSSION**

Patients with HFI display an innate aversion to sweet foods, fruit and vegetables [19], and HFI treatment consists precisely of a FSS-restricted diet for life [6]. Therefore, these patients are at risk of presenting some vitamin deficiencies. Since to the best of our knowledge there is no published data on vitamin status in HFI patients, the aim of this study was to assess vitamin C and folate status and supplementation practices in a nationwide cohort of HFI patients.

Our data shows that, although most HFI patients (69%) received vitamin C supplementation, vitamin C hypovitaminosis/deficiency was common. Noticeably, five HFI patients (15.6%) presented vitamin C plasma levels below 11 µmol/L, regarded by some authors as severe deficiency [16, 20]. Concerning folic acid, 50% of HFI patients received supplementation, and only one patient presented folate deficiency.

In this study we have used the PRI values, which indicate the level of nutrient intake that is adequate for virtually all people in a population group [21], suggested by the European Food Safety Authority as the dietary reference values for vitamin C and folate acid [16, 22]. In our cohort of HFI participants, the majority presented vitamin C (96.7%) and folate (90%) daily intake below the recommended PRI. Vitamin C dietary intake was especially low in HFI patients compared to the healthy controls, due to the fact that fruit and vegetables are the main sources of vitamin C. HFI patients under treatment consume scarce amounts of vegetables and, when they eat them, they usually boil them to lower their content in fructose. The fact that vitamin C is a temperature-sensitive vitamin and is easily degraded during boiling [23] makes it even harder to reach the recommended vitamin C dietary reference value for patients with HFI.

There are no clinical guidelines for HFI management and, although there is no published data on vitamin status in HFI patients except for some anecdotal clinical cases [24, 25], supplementation with vitamin C and/or folic acid is common.
Table 2. Vitamin C and folate dietary intake, supplementation and circulating levels in HFI patients (dietary intake data not available in two subjects).

| Patient No. | Mult. name | Vitamin C | Folic acid/folate |
|-------------|------------|-----------|------------------|
|             | Dietary intake | Supplementation (mg/day) | Conc. (µmol/L) | Dietary intake | Supplementation (µg/day) | Conc. (nmol/L) |
|             | mg/day | Single | Mult. | Total | Plasma | µg/day | Single | Mult. | Total | Serum |
| 1           | Supradyn® EE | 50.9 | 250 | 90 | 340 | 82.9 | 266 | 0 | 100 | 100 | 35.1 |
| 2           | 46.6 | 0 | 0 | 0 | 34.1 | 145 | 0 | 0 | 0 | 6.1 |
| 3           | 40.0 | 0 | 0 | 0 | 58.5 | 201 | 0 | 0 | 0 | 12.0 |
| 4           | 29.9 | 0 | 0 | 0 | 44.9 | 168 | 0 | 0 | 0 | 8.4 |
| 5           | 23.8 | 0 | 0 | 0 | 6.2 | 113 | 5000 | 0 | 5000 | 38.1 |
| 6           | 20.6 | 200 | 0 | 200 | 38.0 | 130 | 2100 | 0 | 2100 | 11.3 |
| 7           | 12.1 | 250 | 0 | 250 | 94.8 | 189 | 5000 | 0 | 5000 | 54.4 |
| 8           | 21.7 | 250 | 0 | 250 | 73.8 | 184 | 0 | 0 | 0 | 13.4 |
| 9           | ViMin 50 NM | 64.1 | 0 | 30 | 30 | 42.6 | 208 | 0 | 100 | 100 | 16.5 |
| 10         | ViMin 50 NM | 41.5 | 0 | 30 | 30 | 19.3 | 122 | 0 | 100 | 100 | 8.6 |
| 11         | 35.4 | 0 | 0 | 0 | 5.7 | 257 | 0 | 0 | 0 | 11.1 |
| 12         | 11.5 | 20 | 0 | 20 | 76.7 | 206 | 0 | 0 | 0 | 42.1 |
| 13         | 13.3 | 500 | 0 | 500 | 39.7 | 141 | 2500 | 0 | 2500 | 47.1 |
| 14         | 12.1 | 0 | 0 | 0 | 76.7 | 79 | 0 | 0 | 0 | 15.2 |
| 15         | Supradyn® AW | 15.5 | 0 | 80 | 80 | 6.8 | 144 | 5000 | 200 | 5200 | 32.0 |
| 16         | Supradyn® Active | 13.4 | 0 | 80 | 80 | 7.4 | 158 | 5000 | 200 | 5200 | 54.4 |
| 17         | 17.5 | 0 | 0 | 0 | 31.8 | 216 | 0 | 0 | 0 | 17.7 |
| 18         | 19.3 | 0 | 0 | 0 | 26.7 | 197 | 0 | 0 | 0 | 15.4 |
| 19         | 34.5 | 0 | 0 | 0 | 82.9 | 266 | 0 | 0 | 0 | 24.5 |
| 20         | Supradyn® Active | 39.2 | 0 | 80 | 80 | 103.3 | 153 | 0 | 200 | 200 | 12.9 |
| 21         | Supradyn® Prot. | 15.6 | 46 | 20 | 66 | 95.4 | 132 | 700 | 0 | 700 | 45.8 |
| 22         | ViMin 50 NM | 66.6 | 0 | 0 | 0 | 57.3 | 304 | 0 | 0 | 0 | 10.7 |
| 23         | Nu U nutrition | 16.4 | 1000 | 100 | 1100 | 138.0 | 129 | 0 | 200 | 200 | 38.5 |
| 24         | Supradyn® Prot. | 76.1 | 225 | 29 | 254 | 60.2 | 229 | 300 | 0 | 300 | 29.5 |
| 25         | 28.3 | 50 | 0 | 50 | 67.0 | 172 | 300 | 0 | 300 | 38.5 |
| 26         | 23.8 | 200 | 0 | 200 | 39.2 | 208 | 0 | 0 | 0 | 18.6 |
| 27         | 22.5 | 200 | 0 | 200 | 76.1 | 183 | 0 | 0 | 0 | 17.4 |
| 28         | 42.0 | 0 | 0 | 0 | 6.8 | 304 | 0 | 0 | 0 | 24.9 |
| 29         | 6.4 | 1000 | 0 | 1000 | 53.9 | 132 | 0 | 0 | 0 | 31.3 |
| 30         | 76.1 | 50 | 0 | 50 | 21.6 | 281 | 0 | 0 | 0 | 25.8 |
| 31         | 66.6 | 0 | 0 | 0 | 57.3 | 304 | 0 | 0 | 0 | 10.7 |
| 32         | Supradyn® Prot. | 43.4 | 0 | 20 | 20 | 57.9 | 195 | 200 | 0 | 200 | 54.4 |

*Total column refers to the sum of single vitamin and multivitamin supplementation. Dietary intake below population reference intake (PRI) [16, 22] and vitamin levels indicating deficiency [16–18] are marked in bold. Mult. Multivitamin, EE Extra Energy, AW Active Woman, Prot. Protovit.
The most relevant finding of the present study is that the HFI patients that did not consume vitamin C supplements presented a higher percentage of vitamin C deficiency than the healthy control subjects, providing for the first time evidence for the indication of vitamin C supplementation in patients with HFI under a FSS-restricted diet.

Regarding folate, patients that did not receive folic acid supplementation presented lower circulating levels than healthy controls and supplemented HFI patients. However, there was only one HFI patient with folate deficiency. This observation is reasonable as vitamin C is found only in fresh fruits and vegetables, which are very limited in the diet of HFI patients, whereas folate can be found also in other food sources permitted in their diet, such as meat, milk, and eggs [7].

Our study, with data of HFI patients from 11 different centres, shows great heterogeneity in clinical practice regarding folic acid and vitamin C supplementation in HFI patients in Spain. This can be explained by the lack of clinical guidelines and data on vitamin status in this rare disease. Furthermore, the variability in the nutritional approach that we describe in this study is common in other rare inherited metabolic disorders like phenylketonuria, urea cycle disorders, and methylmalonic acidemia [26–28].

The most relevant finding of the present study is that the HFI patients that did not consume vitamin C supplements presented a higher percentage of vitamin C deficiency than the healthy control subjects, providing for the first time evidence for the indication of vitamin C supplementation in patients with HFI under a FSS-restricted diet.

Regarding folate, patients that did not receive folic acid supplementation presented lower circulating levels than healthy controls and supplemented HFI patients. However, there was only one HFI patient with folate deficiency. This observation is reasonable as vitamin C is found only in fresh fruits and vegetables, which are very limited in the diet of HFI patients, whereas folate can be found also in other food sources permitted in their diet, such as meat, milk, and eggs [7].

Our study, with data of HFI patients from 11 different centres, shows great heterogeneity in clinical practice regarding folic acid and vitamin C supplementation in HFI patients in Spain. This can be explained by the lack of clinical guidelines and data on vitamin status in this rare disease. Furthermore, the variability in the nutritional approach that we describe in this study is common in other rare inherited metabolic disorders like phenylketonuria, urea cycle disorders, and methylmalonic acidemia [26–28].

Moreover, in our study, the high percentage of vitamin C hypovitaminosis/deficiency in HFI patients despite supplementation...
is to be noted, as 18.2% of HFI patients supplemented with vitamin C presented vitamin C hypovitaminosis/deficiency, and 9.1% vitamin C deficiency. This may be due to the fact that many patients received vitamin C supplementation at a low dosage, mainly those who received it from multivitamin supplementation. Thus, supplementation should be prescribed in order to provide at least the recommended dietary reference values [21], and vitamin status should be monitored regularly.

Once the diagnosis has been made and treatment implemented, HFI is thought to be a benign disease, as when a FSS-restricted diet is started early in life and adherence is maintained the prognosis for individuals with HFI is expected to be excellent [29]. However, some long-term complications have recently been described in patients on a FSS-restricted diet, such as hepatic steatosis [8]. In this study, we show that vitamin C deficiency is also common in HFI patients. Attention must be paid to detecting more potential sub-optimal outcomes in these patients to optimise their follow-up and treatment.

Strengths of this study include a comprehensive assessment of vitamin C and folate status, dietary intake and supplementation practices in a large nationwide cohort of HFI patients, compared to a cohort of age and sex-paired healthy control subjects. We acknowledge that the statistical power of this study would increase with a larger number of participants. However, we were able to enrol a fairly good number of patients and healthy control subjects, considering the low prevalence of HFI. In addition, adherence to vitamin supplementation prescription in HFI patients was not assessed and, although the same researcher instructed all participants, the nutritional records of dietary intake could be subjective.

CONCLUSIONS
Our results provide evidence for the first time supporting vitamin C supplementation in patients with HFI. There is great heterogeneity in vitamin supplementation practices and, despite follow-up at specialised centres, vitamin C insufficiency/deficiency is common in HFI patients. Further research is warranted to establish optimal doses of vitamin C and the need for folic acid supplementation in these patients.

DATA AVAILABILITY
Additional data are available from the corresponding author on reasonable request.

REFERENCES
1. Ali M, Rellos P, Cox TM. Hereditary fructose intolerance. J Med Genet. 1998;35:353–65.
2. Rutter WJ, Rajkumar T, Penhoet O, Kochman M, Valentine R. Aldolase variants: structure and physiological significance. Ann N Y Acad Sci. 1968;151:102–17.
3. Pinheiro FC, Sperb-Ludwig F, Schwartz IVD. Epidemiological aspects of hereditary fructose intolerance: a database study. Hum Mutat. 2019;42:1548–66.
4. Morris RC. An experimental renal acidification defect in patients with hereditary fructose intolerance: II. Its distinction from classic renal tubular acidosis; its resemblance to the renal acidification defect associated with the f ancori syndrome of children with cystinosis. J Clin Invest. 1968;47:1648–63.
5. Baerlocher K, Gitzelmann R, Steinmann B, Gitzelmann-Cumarasamy N. Hereditary fructose intolerance in early childhood: a major diagnostic challenge. Survey of 20 symptomatic cases. Helvetica Paediatrica Acta. 1978;33:465–87.
6. Odiève M, Gentil C, Gautier M, Alagille D. Hereditary fructose intolerance in childhood: diagnosis, management, and course in 55 patients. Am J Dis Child. 1978;132:605–8.
7. Hegedüs VS, Shamon T. Hereditary fructose intolerance. In: StatPears [Internet]. Treasure Island (FL): StatPearls Publishing; 2021. https://pubmed.ncbi.nlm.nih.gov/32644528.
8. Aldámiz-Echeverría L, de Las Heras J, Coule ML, Alcalde C, Vitoria I, Bueno M, et al. Non-alcoholic fatty liver in hereditary fructose intolerance. Clin Nutr (Edinb, Scotl). 2020;39:495–9.
AUTHOR CONTRIBUTIONS
Conceived and designed the study: JHM; Funding acquisition, JHM; Analysed the data, AC, CA, AB-Q, EC-V, LC, SC-C, PC, MLC, DG-A, IG, TH, EI-G, DMC, MM, CP-G, EPJ, LP-Q, PS-P, JS-N, MUS, IVM, JHM; Contributed reagents/materials/analysis tools, AC, CA, AB-Q, EC-V, LC, SC-C, PC, MLC, DG-A, IG, TH, EI-G, DMC, MM, CP-G, EPJ, LP-Q, PS-P, JS-N, MUS, IVM, JHM; Wrote the paper, JHM, AC; Writing-review & editing, AC, C-C, PC, MLC, DG-A, IG, TH, EI-G, DMC, MM, CP-G, EPJ, LP-Q, PS-P, JS-N, MUS, IVM, JHM. All authors have read and agreed to the published version of the paper.

FUNDING
This work was supported by Exp. No. 2018111095, Basque Government, Health Department; FEDER, the Spanish Federation for Rare Diseases (FI18053); and Danone-Nutricia-Metabolics, which was not involved in the study hypothesis/design, execution, analysis, or interpretation.

COMPETING INTERESTS
The authors declare no competing interests.

ADDITIONAL INFORMATION
Correspondence and requests for materials should be addressed to Javier de las Heras.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022, corrected publication 2023